A 36-year-old female client presents to the psychiatric-mental health nurse practitioner. She has been stable for 1 year but says her buprenorphine regimen has not been working since she started a new medication prescribed by her primary care provider. Which medication most likely contributed to the decrease in buprenorphine efficacy?

Choice A reason: Carbamazepine is a known inducer of the cytochrome P450 3A4 enzyme, which metabolizes buprenorphine. Its induction leads to increased metabolism and reduced plasma levels of buprenorphine, thereby decreasing its efficacy. This interaction can result in withdrawal symptoms or reduced control of opioid use disorder. Choice B reason: Amitriptyline is a tricyclic antidepressant that does not significantly affect buprenorphine metabolism. While it may have sedative effects or interact with other CNS depressants, it is not known to reduce buprenorphine efficacy. Choice C reason: Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and a CYP2D6 inhibitor. It does not significantly impact buprenorphine levels or efficacy. Its interaction profile is more relevant to serotonergic drugs than opioids. Choice D reason: Erythromycin is a macrolide antibiotic and a CYP3A4 inhibitor. It can increase buprenorphine levels rather than decrease them. Therefore, it would not contribute to reduced efficacy but might increase side effects.